World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
76
Citations
24537
World Ranking
18691
National Ranking
985

Overview

Diamant Thaçi is affiliated with the University of Lübeck in Germany. Their research primarily spans the fields of Medicine, Immunology, and Microbiology, with a focus on several key subfields including Immunology, Dermatology, Rheumatology, Immunology and Allergy, and Pathology and Forensic Medicine.

The scientist's work covers a range of main topics, notably:

  • Psoriasis: Treatment and Pathogenesis
  • Dermatology and Skin Diseases
  • Autoimmune Bullous Skin Diseases
  • Asthma and respiratory diseases
  • Allergic Rhinitis and Sensitization
  • Pharmaceutical studies and practices
  • Urticaria and Related Conditions

Diamant Thaçi has published extensively in a number of scientific journals. Frequent venues include:

  • Journal of the American Academy of Dermatology
  • SKIN The Journal of Cutaneous Medicine
  • Journal of the European Academy of Dermatology and Venereology
  • British Journal of Dermatology
  • Dermatology and Therapy

Key recent papers authored or co-authored by Diamant Thaçi include:

  • Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials, 2021, The Lancet
  • Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis, 2021, New England Journal of Medicine
  • Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial, 2020, Journal of the American Academy of Dermatology
  • Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial, 2022, Journal of the American Academy of Dermatology
  • Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial, 2022, Journal of the American Academy of Dermatology

Among frequent collaborators, Diamant Thaçi has worked significantly with:

  • Richard B. Warren
  • Mark Lebwohl
  • Andrew Blauvelt
  • Melinda Gooderham
  • Bruce Strober

Best Publications

  • Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

    Lisa A. Beck;Diamant Thaçi;Jennifer D. Hamilton;Neil M. Graham

  • The First European Evidence-Based Consensus on Extra-Intestinal Manifestations in Inflammatory Bowel Disease

    Marcus Harbord;Vito Annese;Stephan R. Vavricka;Matthieu Allez

  • Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

    Diamant Thaçi;Eric L Simpson;Lisa A Beck;Thomas Bieber

  • Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

    Diamant Thaçi;Andrew Blauvelt;Kristian Reich;Tsen-Fang Tsai

  • Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

    Kristian Reich;Kim A Papp;Andrew Blauvelt;Stephen K Tyring

  • Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics

    Philip J. Mease;Dafna D. Gladman;Kim A. Papp;Majed M. Khraishi

  • Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

    M. de Bruin-Weller;D. Thaçi;C.H. Smith;K. Reich

  • Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

    Emma Guttman-Yassky;Henrique D. Teixeira;Eric L. Simpson;Kim A. Papp

  • Psoriasis : a possible risk factor for development of coronary artery calcification

    Ralf J. Ludwig;C. Herzog;A. Rostock;Falk Rudiger Ochsendorf

  • Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

    Peter Nash;Bruce Kirkham;Masato Okada;Proton Rahman

  • A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis†

    K.A. Papp;K. Reich;C. Paul;A. Blauvelt

  • Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

    Thomas Bieber;Eric L. Simpson;Jonathan I. Silverberg;Diamant Thaçi

  • Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.

    Kim Papp;Kenneth Gordon;Diamant Thaçi;Akimichi Morita

  • Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

    Amy S. Paller;Amy S. Paller;Elaine C. Siegfried;Elaine C. Siegfried;Diamant Thaçi;Andreas Wollenberg

  • Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.

    Phoebe Rich;B. Sigurgeirsson;D. Thaci;J. P. Ortonne

  • Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials

    K.A. Papp;M.A. Menter;M. Abe;B. Elewski

  • Psoriasis patients show signs of insulin resistance.

    Sandra Boehncke;Diamant Thaci;Heike Beschmann;Ralf J. Ludwig

  • Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

    Andrew Blauvelt;Kristian Reich;Tsen-Fang Tsai;Stephen Tyring

  • Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial

    K. Papp;D. Thaçi;K. Reich;E. Riedl

  • Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

    Emma Guttman-Yassky;Diamant Thaçi;Aileen L. Pangan;H. Chih-ho Hong

Frequent Co-Authors

Matthias Augustin
Matthias Augustin Universität Hamburg
Kim Papp
Kim Papp Probity Medical Research
Kristian Reich
Kristian Reich University of Göttingen
Ulrich Mrowietz
Ulrich Mrowietz Kiel University
Andrew Blauvelt
Andrew Blauvelt Veterans Health Administration
Alice B. Gottlieb
Alice B. Gottlieb Icahn School of Medicine at Mount Sinai
Wolf-Henning Boehncke
Wolf-Henning Boehncke University of Geneva
Mark Lebwohl
Mark Lebwohl Icahn School of Medicine at Mount Sinai
Kenneth B. Gordon
Kenneth B. Gordon Medical College of Wisconsin
Thomas Bieber
Thomas Bieber University of Bonn

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in healthcare doesn’t always mean attending traditional, on-campus medical programs. Today, there are many flexible online degrees and certifications that open the door to rewarding paths in medicine and related fields.

For those seeking advanced clinical roles, cheap online dnp programs offer a cost-effective route to leadership positions in nursing. Pharmacists also have new online options, such as the streamlined 3-year online pharmd, which allows students to earn a doctorate in pharmacy in an accelerated timeframe.

Not all healthcare roles require direct patient care. For those interested in the administrative or data side of medicine, you can pursue a bachelor of health information management online. This degree prepares you for managing patient records, health informatics, and regulatory compliance. Additionally, getting a medical coding certification is a quick way to break into a vital, in-demand healthcare career with flexible remote work opportunities.

Exploring these online programs can help you find the best fit for your skills, schedule, and financial situation as you embark on a career in healthcare.

Best Scientists Citing Diamant Thaçi

Trending Scientists